Immunoregulation by cytokines in autoimmune diabetes

Advances in Experimental Medicine and Biology

Volumn 520, Issue , 2003, Pages 159-193

  Rabinovitch, Alex ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; CYTOKINE; CYTOKINE ANTIBODY; FREUND ADJUVANT; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; LYMPHOTOXIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 6; RECOMBINANT LYMPHOTOXIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; CELL DESTRUCTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPATHOGENIC EFFECT; DRUG EFFECT; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

EID: 0038748325     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0171-8_10     Document Type: Review

References (308)

1. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 1994; 15:516-542.
2. Wilkin TJ. The primary lesion theory of autoimmunity: A speculative hypothesis. Autoimmunity 1990; 7:225-235.
3. Lampeter EF, Homberg M, Quabeck K et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993; 341:1243-1244.
4. Vialettes B, Maraninchi D, San Marco MP et al. Autoimmune polyendocrine failureCType 1 (insulin-dependent) diabetes mellitus and hypothyroidismCafter allogeneic bone marrow transplantation in a patient with lymphoblastic leukaemia. Diabetologia 1993; 36:541-546.
5. Lampeter EB. Discussion remark to Session 24: BMT in autoimmune diseases. Exp Hematol 1993; 21:1155.
6. Calcinaro F, Hao L, Chase HP et al. Detection of cell-mediated immunity in type I diabetes mellitus. J Autoimmun 1992; 5:137-147.
7. Petersen JS, Marshall MO, Bækkeskov S et al. Transfer of Type 1 (insulin-dependent) diabetes mellitus associated autoimmunity to mice with severe combined immunodeficiency (SCID). Diabetologia 1993; 36:510-515.
8. Rossini AA, Greiner DL, Friedman HP et al. Immunopathogenesis of diabetes mellitus. Diabetes Rev 1993; 1:43-75.
9. Singh B, Rabinovitch A. Influence of microbial agents on the development and prevention of autoimmune diabetes. Autoimmunity 1993; 15:209-213.
10. Dardenne M, Lepault F, Bendelac A et al. Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning. Eur J Immunol 1989; 19:889-895.
11. Harada M, Makino S. Promotion of spontaneous diabetes in nonobese diabetes-prone mice by cyclophosphamide. Diabetologia 1984; 27:604-606.
12. Yasunami R, Bach JF. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 1988; 18:481-484.
13. Bendelac A, Carnaud C, Boitard C et al. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 1987; 166:823-832.
14. Haskins K, McDuffie M. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 1990; 249:1433-1436.
15. Sempé P, Richard MF, Bach JF et al. Evidence of CD4+ regulatory T cells in the nonobese diabetic male mouse. Diabetologia 1994; 37:337-343.
16. Boitard C, Yasunami R, Dardenne M et al. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med 1989; 169:1669-1680.
17. Pankewycz OG, Guan JX, Benedict JF. A protective NOD islet-infiltrating CD8+ T cell clone, I.W. 2.15, has in vitro immunosuppressive properties. Eur J Immunol 1992; 22:2017-2023.
18. Pankewycz O, Strom TB, Rubin-Kelley VE. Islet-infiltrating T cell clones from nonobese diabetic mice that promote or prevent accelerated onset diabetes. Eur J Immunol 1991; 21:873-879.
19. Diaz-Gallo C, Moscovitch-Lopatin M, Strom TB et al. An anergic, islet-infiltrating T-cell clone that suppresses murine diabetes secretes a factor that blocks interleukin 2/interleukin 4-dependent proliferation. Proc Natl Acad Sci USA 1992; 89:8656-8660.
20. Boitard C, Bendelac A, Richard MF et al. Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: Transfer of protection by splenic T cells. Proc Natl Acad Sci USA 1988; 85:9719-9723.
21. Greiner DL, Mordes JP, Handler ES et al. Depletion of RT6.1+ T lymphocytes induces diabetes in resistant biobreeding/Worcester (BB/W) rats. J Exp Med 1987; 166:461-475.
22. Rossini AA, Faustman D, Woda BA et al. Lymphocyte transfusions prevent diabetes in the BioBreeding/Worcester rat. J Clin Invest 1984; 74:39-46.
23. Thorpe R, Wadhwa M, Bird CR et al. Detection and measurement of cytokines. Blood Rev 1992; 6:133-148.
24. Mosmann TR, Cherwinski H, Bond MW et al. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-2357.
25. Cherwinski HC, Schumacher JH, Brown KD et al. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays and monoclonal antibodies. J. Exp Med 1987; 166:1229-1244.
26. Del Prete GF, De Carli M, Mastromauro C et al. Purified protein derivative (PPD) of Mycobacterium tuberculosis and excretory-secretory antigen(s) (TES) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profiles of cytokine production. J Clin Invest 1991; 88:346-350.
27. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138-146.
28. Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-173.
29. Chen Y, Kuchroo VK, Inobe J et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265:1237-1240.
30. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12:227-257.
31. Fitch FW, McKisic MD, Lancki DW et al. Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol 1993; 11:29-48.
32. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T-cells. Annu Rev Immunol 1994; 12:635-673.
33. Moore KW, O'Garra A, de Waal Malefyt R et al. Interleukin 10. Annu Rev Immunol 1993; 11:165-190.
34. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13:251-276.
35. Ding L, Linsley PS, Huang L-Y et al. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the upregulation of B7 expression. J Immunol 1993; 151:1224-1234.
36. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993; 23:3043-3049.
37. Mosmann T. Complexity or coherence? Cytokine secretion by B cells. Nature Immunol 2000; 1:465-466.
38. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994; 15:575-581.
39. Kolb H. Benign versus destructive insulitis. Diabetes Metab Rev 1997; 13:139-146.
40. Shehadeh NN, LaRosa F, Lafferty KJ. Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimmun 1993; 6:291-300.
41. Campbell IL, Kay TWH, Oxbrow L et al. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991; 87:739-742.
42. Rothe H, Faust A, Schade U et al. Cyclophosphamide treatment of female nonobese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia 1994; 37:1154-1158.
43. Pilstrom B, Bjork L, Bohme J. Demonstration of a TH1 cytokine profile in the late phase of NOD insulitis. Cytokine 1995; 7:806-814.
44. Rabinovitch A, Suarez-Pinzon WL, Sorensen O et al. IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J Immunol 1995; 154:4874-4882.
45. Muir A, Peck A, ClareSalzler M et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-γ transcription. J Clin Invest 1995; 95:628-634.
46. Hancock WW, Polanski M, Zhang J et al. Suppression of insulitis in nonobese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-β, and prostaglandin-E. Am J Pathol 1995; 147:1193-1199.
47. Rabinovitch A, Suarez-Pinzon WL, Sorensen O et al. Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: Identification of iNOS-expressing cells and relationships to cytokines in the islets. Endocrinology 1996; 137:2093-2099.
48. Zheng XX, Steele AW, Hancock WW et al. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 1997; 158:4507-4513.
49. Kolb H, Wörz-Pagenstert U, Kleemann R et al. Cytokine gene expression in the BB rat pancreas: Natural course and impact of bacterial vaccines. Diabetologia 1996; 39:1448-1454.
50. Zipris D, Greiner DL, Malkani S et al. Cytokine gene expression in islets and thyroids of BB rats. IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats. J Immunol 1996; 156:1315-1321.
51. Rabinovitch A, Suarez-Pinzon W, El-Sheikh A et al. Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: Expression of Th1 cytokines correlates with beta-cell destructive insulitis and IDDM. Diabetes 1996; 45:749-754.
52. Chung Y-H, Jun H-S, Kang Y et al. Role of macrophages and macrophage-derived cytokines in the pathogenesis of Kilham rat virus-induced autoimmune diabetes in diabetes-resistant BioBreeding rats. J Immunol 1997; 159:466-471.
53. Rabinovitch A, Sorensen O, Suarez-Pinzon WL et al. Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: interleukin 2 and interferon gamma mRNA expression correlate with graft rejection and interleukin 10 with graft survival. Diabetologia 1994; 37:833-837.
54. Suarez-Pinzon W, Rajotte RV, Mosmann TR et al. Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction. Diabetes 1996; 45:1350-1357.
55. Rothe H, Burkart V, Faust A et al. Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in nonobese diabetic mice. Diabetologia 1996; 39:119-122.
56. Rabinovitch A, Suarez-Pinzon WL, Sorensen O. Interleukin 12 mRNA expression in islets correlates with β-cell destruction in NOD mice. J Autoimmun 1996; 9:645-651.
57. Rothe H, Jenkins NA, Copeland NG et al. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. J Clin Invest 1997; 99:469-474.
58. Rothe H, Hibino T, Itoh Y et al. Systemic production of interferon-gamma inducing factor (IGIF) versus local IFN-γ expression involved in the development of Th1 insulitis in NOD mice. J Autoimmun 1997; 10:251-256.
59. Fox CJ, Danska JS. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. J Immunol 1997; 158:2414-2424.
60. Arreaza GA, Cameron MJ, Jaramillo A et al. Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4 dependent mechanism. J Clin Invest 1997; 100:2243-2253.
61. Cetkovic-Cvrlje M, Gerling IC, Muir A et al. Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate β-cell antigens. Diabetes 1997; 46:1975-1982.
62. Huang X, Hultgren B, Dybdal N et al. Islet expression of interferon-γ precedes diabetes in both the BB rat and streptozotocin-treated mice. Immunity 1994; 1:469-478.
63. Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987; 2:1423-1427.
64. Huang X, Yuan J, Goddard A et al. Interferon expression in the pancreases of patients with type 1 diabetes. Diabetes 1995; 44:658-664.
65. Somoza N, Vargas F, Roura-Mir C et al. Pancreas in recent onset insulin-dependent diabetes mellitus: changes in HLA, adhesion molecules and autoantigens, restricted TCR Vβ usage, and cytokine profile. J Immunol 1994; 153:1360-1377.
66. Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man: Macrophages, lymphocytes, and interferon-γ containing cells. J Pathol 1991; 165:97-103.
67. Yamagata K, Nakajima H, Tomita K et al. Dominant TCR α-chain clonotypes and interferon-_are expressed in the pancreas of patients with recent-onset insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1996; 34:37-46.
68. Mandrup-Poulsen T, Helqvist S, Wogensen LD et al. Cytokines and free radicals as effector molecules in the destruction of pancreatic β-cells. Curr Top Microbiol Immunol 1990; 164:169-193.
69. Rabinovitch A. Roles of cytokines in IDDM pathogenesis and islet β-cell destruction. Diabetes Rev 1993; 1:215-240.
70. Bolaffi JL, Nowlain RE, Cruz L et al. Progressive damage of cultured pancreatic islets after single early exposure to streptozotocin. Diabetes 1986; 35:1027-1033.
71. Pipeleers D, Van de Winkel M. Pancreatic β cells possess defense mechanisms against cell-specific toxicity. Proc Natl Acad Sci USA 1986; 83:5267-5271.
72. Ling Z, In't Veld PA, Pipeleers DG. Interaction of interleukin-1 with islet β-cells. Distinction between indirect, aspecific cytotoxicity and direct, specific functional suppression. Diabetes 1993; 42:56-65.
73. Poo W-J, Conrad L, Janeway Jr CA. Receptor-directed focusing of lymphokine release by helper T cells. Nature 1988; 332:378-380.
74. Kurt-Jones EA, Beller DI, Mizel SB et al. Identification of a membrane associated interleukin-1 in macrophages. Proc Natl Acad Sci USA 1985; 82:1204-1208.
75. Kriegler M, Perez C, DeFay K et al. A novel form of TNF/cachetin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53:45-53.
76. Sutton R, Gray DWR, McShane P et al. The specificity of rejection and the absence of susceptibility of pancreatic islet β-cells to nonspecific immune destruction in mixed strain islets grafted beneath the renal capsule in the rat. J Exp Med 1989; 170:751-762.
77. Korsgren O, Jansson L. Characterization of mixed syngeneic-allogeneic and syngeneic-xenogeneic islet-graft rejections in mice. Evidence of functional impairment of the remaining syngeneic islets in xenograft rejections. J Clin Invest 1994; 93:1113-1119.
78. Thomas HE, Parker JL, Schreiber RD et al. IFN-γ action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J Clin Invest 1998; 102:1249-1257.
79. Corbett JA, McDaniel ML. Intraislet release of IL-1 inhibits β-cell function by inducing β-cell expression of iNOS. J Exp Med 1995; 181:559-568.
80. Arnush M, Heitmeier MR, Scarim AL et al. IL-1 produced and released endogenously within human islets inhibits β cell function. J Clin Invest 1998; 102:516-526.
81. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39:1005-1029.
82. Eizirik DL, Pavlovic D. Is there a role for nitric oxide in β-cell dysfunction and damage in IDDM? Diabetes Metab Rev 1997; 13:293-307.
83. Suarez-Pinzon WL, Szabó C, Rabinovitch A. Development of autoimmune diabetes in NOD mice is associated with the formation of peroxynitrite in pancreatic islet β-cells. Diabetes 1997; 46:907-911.
84. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55:1139-1149.
85. Sarvetnick N, Liggitt D, Pitts SL et al. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell 1988; 52:773-782.
86. Sarvetnick N, Shizuru J, Liggitt D et al. Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ. Nature 1990; 346:844-847.
87. Stewart TA, Hultgren B, Huang X et al. Induction of type 1 diabetes by interferon-α in transgenic mice. Science 1993; 260:1942-1946.
88. Chakrabarti D, Hultgren B, Stewart TA. IFN-α induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 1996; 157:522-528.
89. Allison J, Malcolm L, Chosich N et al. Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of interleukin-2 in islet β cells. Eur J Immunol 1992; 22:1115-1121.
90. Allison J, Oxbrow L, Miller JFA. Consequences of in situ production of IL-2 for islet cell death. Int Immunol 1994; 6:541-549.
91. Allison J, McClive P, Oxbrow L et al. Genetic requirements for acceleration of diabetes in nonobese diabetic mice expressing interleukin-2 in islet β-cells. Eur J Immunol 1994; 24:2535-2541.
92. Higuchi Y, Herrera P, Muniesa P et al. Expression of a tumour necrosis factor α transgene in murine pancreatic β cells results in severe and permanent insulitis without evolution towards diabetes. J Exp Med 1992; 176:1719-1731.
93. Picarella DE, Kratz A, Li C et al. Transgenic tumor necrosis factor (TNF)-α production in pancreatic islets leads to insulitis, not diabetes. Distinct patterns of inflammation in TNF-α and TNF-β transgenic mice. J Immunol 1993; 150:4136-4150.
94. Guerder S, Meyerhoff J, Flavell R. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1994; 1:155-166.
95. Grewal IS, Grewal KD, Wong FS et al. Local expression of transgene encoded TNF-α in islets prevents autoimmune diabetes in NOD mice by preventing the development of autoreactive islet specific T cells. J Exp Med 1996; 184:1963-1974.
96. Sarvetnick N. Mechanisms of cytokine-mediated localized immunoprotection. J Exp Med 1996; 184:1597-1600.
97. McSorley SJ, Soldera S, Malherbe L et al. Immunological tolerance to a pancreatic antigen as a result of local expression of TNFα by islet β cells. Immunity 1997; 7:401-409.
98. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184:1093-1099.
99. Mueller R, Bradley LM, Krahl T et al. Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity 1997; 7:411-418.
100. Campbell IL, Hobbs MV, Dockter J et al. Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. Am J Pathol 1994; 145:157-166.
101. Di Cosmo BF, Picarella D, Flavell RA. Local production of human IL-6 promotes insulitis but retards the onset of insulin-dependent diabetes mellitus in nonobese diabetic mice. Int Immunol 1994; 6:1829-1837.
102. Wogensen L, Huang X, Sarvetnick N. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans. J Exp Med 1993; 178:175-185.
103. Wogensen L, Lee M-S, Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med 1994; 179:1379-1384.
104. Moritani M, Yoshimoto K, Tashiro F et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in nonobese diabetic mice. Int Immunol 1994; 6:1927-1936.
105. King C, Davies J, Mueller R et al. TGF-β1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 1998; 8:601-613.
106. Moritani M, Yoshimoto K, Wong SF et al. Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-β1. J Clin Invest 1998; 102:499-506.
107. Wilson CA, Jacobs C, Baker P et al. IL-1β modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat. J Immunol 1990; 144:3784-3788.
108. Jacob CO, Asiso S, Michie SA et al. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): Similarities between TNF-α and interleukin-1. Proc Natl Acad Sci USA 1990; 87:968-972.
109. Serreze DV, Hamaguchi K, Leiter EH. Immunostimulation circumvents diabetes in NOD/Lt mice. J Autoimmun 1989; 2:759-776.
110. Zielasek J, Burkart V, Naylor P et al. Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats. Immunology 1990; 69:209-214.
111. Rapoport MJ, Jaramillo A, Zipris D et al. Interleukin-4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178:87-99.
112. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 (rHU IL-10) prevents the onset of diabetes in the nonobese diabetic (NOD) mouse. Clin Immunol Immunopathol 1994; 71:169-175.
113. Satoh J, Seino H, Abo T et al. Recombinant human tumor necrosis factor-α suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989; 84:1345-1348.
114. Satoh J, Seino H, Shintani S et al. Inhibition of type I diabetes in BB rats with recombinant human tumor necrosis factor-α. J Immunol 1990; 145:1395-1399.
115. Seino H, Takahashi K, Satoh J et al. Prevention of autoimmune diabetes with lymphotoxin in NOD mice. Diabetes 1993; 42:398-404.
116. Takahashi K, Satoh J, Seino H et al. Prevention of type I diabetes with lymphotoxin in BB rats. Clin Immunol Immunopathol 1993; 69:318-323.
117. Zaccone P, Phillips J, Conger I et al. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes 1999; 48:1522-1528.
118. Serreze DV, Leiter EH. Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. J Immunol 1988; 140:3801-3807.
119. Lapchak PH, Guilbert LJ, Rabinovitch A. Tumor necrosis factor production is deficient in diabetes-prone BB rats and can be corrected by complete Freund's adjuvant: A possible immunoregulatory role of tumor necrosis factor in the prevention of diabetes. Clin Immunol Immunopathol 1992; 65:129-134.
120. Cameron MJ, Arreaza GA, Zucker P et al. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 1997; 159:4686-4692
121. Sobel DO, Ahvazi B. α-interferon inhibits the development of diabetes in NOD mice. Diabetes 1998; 47:1867-1872.
122. Sobel DO, Creswell K, Yoon J-W et al. Alpha interferon administration paradoxically inhibits the development of diabetes in BB rats. Life Sciences 1998; 62:1293-1302.
123. Campbell IL, Oxbrow L, Harrison LC. Reduction in insulitis following administration of IFN-gamma and TNF-alpha in the NOD mouse. J Autoimmun 1991; 4:249-262.
124. Nicoletti F, Zaccone P, Di Marco R et al. Paradoxical antidiabetogenic effect of γ-interferon in DP-BB rats. Diabetes 1998; 47:32-38.
125. + T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest 1995; 95:2711-2719.
126. Willenborg DO, Fordham S, Bernard CCA et al. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996; 157:3223-3227.
127. Mandrup-Poulsen T, Nerup J, Reimers JI et al. Cytokines and the endocrine system. I. The immunoendocrine network. Eur J Endocrinol 1995; 133:660-671.
128. + T cells in vitro. J Immunol 1996; 156:2406-2412.
129. + lymphocytes. J Immunol 1997; 158:5589-5595.
130. Trembleau S, Penna G, Bosi E et al. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995; 181:817-821.
131. O'Hara Jr RM, Henderson SL, Nagelin AM. Prevention of a Th1 disease by a Th1 cytokine: IL-12 and diabetes in NOD mice. Ann NY Acad Sci 1996; 795:241-249.
132. Yang X-D, Tisch R, Singer SM et al. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994; 180:995-1004.
133. Cope AP, Liblau RS, Yang X-D et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997; 185:1573-1584.
134. Rabinovitch A, Suarez-Pinzon WL, Sorensen O et al. TNF-α down-regulates type 1 cytokines and prolongs survival of syngeneic islet grafts in nonobese diabetic mice. J Immunol 1997; 159:6298-6303.
135. + T cell pathway circumventing the requirement for CD4+ T- and B-lymphocytes. J Immunol 1998; 161:4420-4427.
136. Piccirillo CA, Chang Y, Prud=homme GJ. TGF-β1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J Immunol 1998; 161:3950-3956.
137. Suarez-Pinzon W, Korbutt GS, Power R et al. Testicular Sertoli cells protect islet β-cells from autoimmune destruction in NOD mice by a transforming growth factor-β1-dependent mechanism. Diabetes 2000; 49:1810-1818.
138. Nicoletti F, Dimarco R, Barcellini W et al. Protection from experimental autoimmune diabetes in the nonobese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol 1994; 24:1843-1847.
139. Cailleau C, Diu-Hercend A, Ruuth E et al. Treatment with neutralizing antibodies specific for IL-1β prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 1997; 46:937-940.
140. Sandberg J-O, Eizirik DL, Sandler S. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic nonobese diabetic (NOD) mice. Clin Exp Immunol 1997; 108:314-317.
141. Debray-Sachs M, Carnaud C, Boitard C et al. Prevention of diabetes in NOD mice treated with antibody to murine IFN-γ. J Autoimmun 1991; 4:237-248.
142. Nicoletti F, Zaccone P, Di Marco R et al. Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-γ antibody. Endocrinology 1997; 138:281-288.
143. Nicoletti F, Zaccone P, Di Marco R et al. The effects of a nonimmunogenic form of murine soluble interferon-γ receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology 1996; 137:5567-5575.
144. Kurschner C, Ozmen L, Garotta G et al. IFN-gamma receptor-Ig fusion proteins. Half-life, immunogenicity and in vivo activity. J Immunol 1992; 149:4096-4100.
145. Kelley VE, Gaulton GN, Hattori M et al. Anti-interleukin-2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 1988; 140:59-61.
146. PachecoSilva A, Bastos MG, Muggia RA et al. Interleukin-2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. Eur J Immunol 1992; 22:697-702.
147. Hunger RE, Carnaud C, Garcia I et al. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur J Immunol 1997; 27:255-261.
148. Lee M-S, Mueller R, Wicker LS et al. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J Exp Med 1996; 183:2663-2668.
149. Trembleau S, Penna G, Gregori S et al. The role of endogenous IL-12 in the development of spontaneous diabetes in NOD mice. Autoimmunity 1996; 21:A087.
150. Hultgren B, Huang X, Dybdal N et al. Genetic absence of γ-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996; 45:812-817.
151. 2. Diabetologia 1997; 40:641-646.
152. Yasuda H, Nagata M, Arisawa K et al. Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. J Clin Invest 1998; 102:1807-1814.
153. Wang B, André I, Gonzalez A et al. Interferon-γ impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94:13844-13849.
154. Kanagawa O, Xu G, Tevaarwerk A et al. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-γ receptor loci. J Immunol 2000; 164:3919-3923.
155. Serreze DV, Post CM, Chapman HD et al. Interferon-γ receptor signalling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 2000; 49:2007-2011.
156. Hänninen A, Jalkanen S, Salmi M et al. Macrophages, T-cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 1992; 90:1901-1910.
157. Itoh N, Hanafusa T, Miyazaki A et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 1993; 92:2313-2322.
158. Stassi G, De Maria R, Trucco G et al. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997; 186:1193-1200.
159. Kallmann BA, Hüther M, Tubes M et al. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes 1997; 46:237-243.
160. Rapoport MJ, Mor A, Vardi P et al. Decreased secretion of Th2 cytokines precedes up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J Autoimmun 1998; 11:635-642.
161. Berman MA, Sandborg CI, Wang Z et al. Decreased IL-4 production in new onset Type I insulin-dependent diabetes mellitus. J Immunol 1996; 157:4690-4696.
162. Hussain MJ, Peakman M, Gallati H et al. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 1996; 39:60-69.
163. Hussain MJ, Maher J, Warnock T et al. Cytokine overproduction in healthy first degree relatives of patients with IDDM. Diabetologia 1998; 41:343-349.
164. Karlsson MGE, Sederholm Lawesson S, Ludvigsson J. Th1-like dominance in high-risk first-degree relatives of Type 1 diabetic patients. Diabetologia 2000; 43:742-749.
165. Wilson SB, Kent SC, Patton KT et al. Extreme Th1 bias of regulatory Vα24JαQ T cells in type 1 diabetes. Nature 1998; 391:177-181.
166. Fowell D, McKnight AJ, Powrie F et al. Subsets of CD4+ T-cells and their roles in the induction and prevention of autoimmunity. Immunol Rev 1991; 123:37-64.
167. Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med 1993; 177:627-636.
168. + cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Diabetes 1996; 45:71-78.
169. Zekzer D, Wong FS, Ayalon O et al. GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 1998; 101:68-73.
170. + β islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice. J Exp Med 1995; 182:87-97.
171. Han H-S, Jun H-S, Utsugi T et al. A new type of CD4+ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmun 1996; 9:331-339.
172. Zekzer D, Wong FS, Wen L et al. Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse. Diabetes 1997; 46:1124-1132.
173. Healey D, Ozegbe P, Arden S et al. In vivo activity and in vitro specificity ofCD4+ Th1 and Th2 T cells derived from the spleens of diabetic NOD mice. J Clin Invest 1995; 95:2979-2985.
174. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268:1185-1188.
175. s (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998; 187:1047-1056.
176. +-like thymocytes in the NOD mouse. Eur J Immunol 1996; 26:2989-2998.
177. s thymocytes. J Autoimmun 1997; 10:279-285.
178. + thymocytes expressing L-selectin mediate Aactive tolerance@ in the nonobese diabetic mouse. J Immunol 1998; 161:2620-2628.
179. Lee K, Kim M, Amano K et al. Preferential infiltration of macrophages
180. Voorbij HA, Jeucken PH, Kabel PJ et al. Dendritic cells and scavenger macrophages in pancreatic islets of prediabetic BB rats. Diabetes 1989; 38:1623-1629.
181. Jansen A, Homo-Delarche F, Hooijkaas H et al. Immunohistochemlcal characterization of monocyte-macrophages and dendritic cells involved in the initiation of insulitis and beta-cell destruction in NOD mice. Diabetes 1994; 43:667-675.
182. Oschilewski U, Kiesel U, Kolb H. Administration of silica prevents diabetes in BB rats. Diabetes 1985; 34:197-199.
183. Lee K, Amano K, Yoon JW. Evidence for initial involvement of macrophages in development of insulitis in NOD mice. Diabetes 1988; 37:989-991.
184. Jun H-S, Yoon C-S, Zbytnuik L et al. The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med 1999; 189:347-358.
185. + T-cells in T-cell receptor transgenic NOD mice. Diabetes 1999; 48:34-42.
186. Serreze DV, Chapman HD, Varnum DS et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new Aspeed congenic@ stock of NOD.Ig mu null mice. J Exp Med 1996; 184:2049-2053.
187. Noorchashm H, Noorchashm N, Kern J et al. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 1997; 46:941-946.
188. Akashi T, Seiho N, Keizo A et al. Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in nonobese diabetic mice. Int Immunol 1997; 9:1159-1164.
189. Shimizu J, Kanagawa O, Unanue ER. Presentation of β-cell antigens to CD4+ and CD8+ T-cells of nonobese diabetic mice. J Immunol 1993; 151:1723-1730.
190. Nepom GT, Erlich H. MHC class-II molecules and autoimmunity. Annu Rev Immunol 1991; 9:493-525.
191. Scott B, Liblau R, Degermann S et al. A role for nonMHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994; 1:73-83.
192. Singer SM, Tisch R, Yang X-D et al. Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes 1998; 47:1570-1577.
193. van Seventer GA, Shimizu Y, Shaw S. Roles of multiple accessory molecules in T-cell activation. Curr Opin Immunol 1991; 3:294-303.
194. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-135.
195. Wong S, Guerder S, Visintin I et al. Expression of the costimulator molecule B7-1 in pancreatic β-cells accelerates diabetes in the NOD mouse. Diabetes 1995; 44:326-329.
196. Lenschow DJ, Ho SC, Sattar H et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181:1145-1155.
197. Balasa B, Krahl T, Patstone G et al. CD40 ligand-CD40 interactions are necessary for the initia-tion of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159:4620-4627.
198. Yagi N, Yokono K, Amano K et al. Expression of intercellular adhesion molecule 1 on pancreatic beta-cells accelerates beta-cell destruction by cytotoxic T-cells in murine autoimmune diabetes. Diabetes 1995; 44:744-752.
199. Moriyama H, Yokono K, Amano K et al. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-/intercellular adhesion molecule-1 pathway. J Immunol 1996; 157:3737-3743.
200. Martin S, Heidenthal E, Schulte B et al. Soluble forms of intercellular adhesion molecule-1 inhibit insulitis and onset of autoimmune diabetes. Diabetologia 1998; 41:1298-1303.
201. Hsieh C-S, Heimberger AB, Gold JS et al. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an αβ T-cell-receptor transgenic system. Proc Natl Acad Sci USA 1992; 89:6065-6069.
202. Seder RA, Paul WE, Davis MM et al. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T-cells from T-cell receptor transgenic mice. J Exp Med 1992; 176:1091-1098.
203. Kolb H, Kolb-Bachofen V, Roep BO. Autoimmune versus inflammatory type I diabetes: a controversy? Immunol Today 1995; 16:170-172.
204. Benoist C, Mathis D. Cell death mediators in autoimmune diabetes C no shortage of suspects. Cell 1997; 89:1-3.
205. + T-cell clones in vivo. Diabetes 1996; 45:1121-1131.
206. Wong FS, Visintin I, Wen L et al. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996; 183:67-76.
207. Miller BJ, Appel MC, O'neil JJ et al. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988; 140:52-58.
208. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T cells from diabetic versus prediabetic NOD.NONThy-1a donors. Diabetes 1993; 42:44-55.
209. Edouard P, Hiserodt JC, Plamondon C et al. CD8+ T-cells are required for adoptive transfer of the BB rat diabetic syndrome. Diabetes 1993; 42:390-397.
210. Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the development of insulitis in nonobese diabetic mice. Eur J Immunol 1993; 23:3358-3360.
211. Young LH, Peterson LB, Wicker LS et al. In vivo expression of perforin by CD8+ lymphocytes in autoimmune disease. Studies on spontaneous and adoptively transferred diabetes in nonobese diabetic mice. J Immunol 1989; 143:3994-3999.
212. Kägi D, Odermatr B, Seiler P et al. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997; 186:989-997.
213. Nagata M, Yokono K, Hayakawa M et al. Destruction of pancreatic islet cells by cytotoxic T lymphocytes in nonobese diabetic mice. J Immunol 1989; 143:1155-1162.
214. Boitard C, Chatenoud L, Debray-Sachs M. In vitro inhibition of pancreatic B cell function by lymphocytes from diabetics with associated autoimmune diseases: A T cell phenomenon. J Immunol 1982; 129:2529-2531.
215. Bradley BJ, Haskins K, La Rosa FG et al. CD8 T cells are not required for islet destruction induced by a CD4+ islet-specific T-cell clone. Diabetes 1992; 41:1603-1608.
216. Wang Y, Pontesilli O, Gill RG et al. The role of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc Natl Acad Sci USA 1991; 88:527-531.
217. Weringer EJ, Like AA. Immune attack on pancreatic islet transplants in the spontaneously diabetic BioBreeding/Worcester (BB/W) rat is not MHC restricted. J Immunol 1985; 134:2383-2386.
218. Kleemann R, Rothe H, Kolb-Bachofen V et al. Transcription and translation of inducible nitric oxide synthase in the pancreas of prediabetic BB rats. FEBS Lett 1993; 328:9-12.
219. Rabinovitch A, Suarez WL, Power RF. Lazaroid antioxidant reduces incidence of diabetes and insulitis in nonobese diabetic mice. J Lab Clin Med 1993; 121:603-607.
220. Mandrup-Poulsen T, Reimers JI, Andersen HU et al. Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1993; 9:295-309.
221. Kay TWH, Campbell IL, Oxbrow L et al. Overexpression of class I major histocompatibility complex accompanies insulitis in the nonobese diabetic mouse and is prevented by anti-interferon-γ antibody. Diabetologia 1991; 34:779-785.
222. Yamada K, Takane-Gyotoku N, Yuan X et al. Mouse islet lysis mediated by interleukin-1-induced Fas. Diabetologia 1996; 39:1306-1312.
223. Stassi G, Todaro M, Richiusa P et al. Expression of apoptosis-inducing CD95 (Fas/Apo-1) on human β-cells sorted by flow-cytometry and cultured in vitro. Transplant Proc 1995; 27:3271-3275.
224. Signore A, Annovazzi A, Procaccini E et al. CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice. Diabetologia 1997; 40:1476-1479.
225. Suarez-Pinzon WL, Sorensen O, Bleackley RC et al. β-cell destruction in NOD mice correlates with Fas (CD95) expression on β-cells and proinflammatory cytokine expression in islets. Diabetes 1999; 48:21-28.
226. Loweth AC, Williams GT, James RFL et al. Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-1β and Fas ligation. Diabetes 1998; 47:727-732.
227. Chervonsky AV, Wang Y, Wong FS et al. The role of Fas in autoimmune diabetes. Cell 1997; 89:17-24.
228. Itoh N, Imagawa A, Hanafusa T et al. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J Exp Med 1997; 186:613-618.
229. Allison J, Strasser A. Mechanisms of β cell death in diabetes: A minor role for CD95. Proc Natl Acad Sci USA 1998; 95:13818-13822.
230. Kim Y-H, Kim S, Kim K-A et al. Apoptosis of pancreatic β-cells detected in accelerated diabetes of NOD mice: no role of Fas-Fas ligand interaction in autoimmune diabetes. Eur J Immunol 1999; 29:455-465.
231. Kim S, Kim KA, Hwang DY et al. Inhibition of autoimmune diabetes by Fas ligand: The paradox is solved. J Immunol 2000; 164:2931-2936.
232. Su X, Hu Q, Kristan JM. Significant role for Fas in the pathogenesis of autoimmune diabetes. J Immunol 2000; 164:2523-2532.
233. + T lymphocytes. J Clin Invest 2000; 105:459-468.
234. Jun H-S, Santamaria P, Lim H-W et al. Absolute requirement of macrophages for the development and activation of β cell cytotoxic T cells in T cell receptor transgenic NOD mice. Diabetes 1999; 48:34-42.
235. Suarez-Pinzon WL, Power RF, Rabinovitch A. Fas ligand-mediated mechanisms are involved in autoimmune destruction of islet beta-cells in nonobese diabetic mice. Diabetologia 2000; 43:1149-1156.
236. + T cells are required for IFN-γ gene expression in pancreatic islets and autoimmune diabetes development in biobreeding rats. J Autoimmun 1999; 12:109-119.
237. + T cell. Immunol Today 1994; 15:107-110.
238. Rus V, Svetic A, Nguyen P et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-Versus-Host Disease. J Immunol 1995; 155:2396-2406.
239. + T cells. J Immunol 1997; 159:2091-2099.
240. Verdaguer J, Schmidt D, Amrani A et al. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J Exp Med 1997; 186:1663-1676.
241. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993; 11:767-804.
242. Doukas J, Mordes JP. T lymphocytes capable of activating endothelial cells in vitro are present in rats with autoimmune diabetes. J Immunol 1993; 150:1036-1046.
243. Santamaria P, Nakhleh RE, Sutherland DE et al. Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes 1992; 41:53-61.
244. Oldstone MB. Prevention of type I diabetes in nonobese diabetic mice by virus infection. Science 1988; 239:500-502.
245. Dyrberg T, Schwimmbeck PL, Oldstone MB. Inhibition of diabetes in BB rats by virus infection. J Clin Invest 1988; 81:928-931.
246. Wilberz S, Partke HJ, Dagnaes-Hansen F et al. Persistent MHV (mouse hepatitis virus) infection reduces the incidence of diabetes mellitus in nonobese diabetic mice. Diabetologia 1991; 34:2-5.
247. Hermitte L, Vialettes B, Naquet P et al. Paradoxical lessening of autoimmune processes in nonobese diabetic mice after infection with the diabetogenic variant of encephalomyocarditis virus. Eur J Immunol 1990; 20:1297-1303.
248. Takei I, Asaba Y, Kasatani T et al. Suppression of development of diabetes in NOD mice by lactate dehydrogenase virus infection. J Autoimmun 1992; 5:665-673.
249. Toyota T, Satoh J, Oya K et al. Streptococcal preparation (OK-432) inhibits development of type I diabetes in NOD mice. Diabetes 1986; 35:496-499.
250. Satoh J, Shintani S, Oya K et al. Treatment with streptococcal preparation (OK-432) suppresses anti-islet autoimmunity and prevents diabetes in BB rats. Diabetes 1988; 37:1188-1194.
251. Kawamura T, Nagata M, Utsugi T et al. Prevention of autoimmune type I diabetes by CD4+ suppressor T-cells in superantigen-treated nonobese diabetic mice. J Immunol 1993; 151:4362-4370.
252. Kino K, Mizumoto K, Sone T et al. An immunomodulating protein Ling Zhi-8 (LZ-8) prevents insulitis in nonobese diabetic mice. Diabetologia 1990; 33:713-718.
253. Elias D, Markovits D, Reshef T et al. Induction and therapy of autoimmune diabetes in the nonobese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci USA 1990; 87:1576-1580.
254. Sadelain MWJ, Qin H-Y, Lauzon J et al. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990; 39:583-589.
255. Sadelain MWJ, Qin H-Y, Sumoski W et al. Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. J Autoimmun 1990; 3:671-680.
256. McInerney MF, Pek SB, Thomas DW. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes 1991; 40:715-725.
257. Pearce RB, Peterson CM. Studies of concanavalin A in nonobese diabetic mice. I. Prevention of insulin-dependent diabetes. J Pharmacol Exp Ther 1991; 258:710-715.
258. Wang T, Singh B, Warnock GL et al. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 1992; 41:114-117.
259. Ulaeto D, Lacy PE, Kipnis DM et al. A T-cell dormant state in the autoimmune process of nonobese diabetic mice treated with complete Freund's adjuvant. Proc Natl Acad Sci USA 1992; 89:3927-3931.
260. Qin H-Y, Suarez WL, Parfrey N et al. Mechanisms of complete Freund's adjuvant protection against diabetes in BB rats: induction of nonspecific suppressor cells. Autoimmunity 1992; 12:193-199.
261. Qin H-Y, Sadelain MWY, Hitchon C et al. Complete Freund's adjuvant-induced T-cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J Immunol 1993; 150:2072-2080.
262. Yagi H, Matsumoto M, Suzuki S et al. Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mouse. I. Generation of suppressor macrophages in spleen cells of BCG-vaccinated mice. Cell Immunol 1991; 138:130-141.
263. Yagi H, Matsumoto M, Kishimoto Y et al. Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mice. II. Suppression of pathogenesis by macrophage transfer from BCG-vaccinated mice. Cell Immunol 1991; 138:142-149.
264. Lakey JRT, Singh B, Warnock GL et al. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice. Transplantation 1994; 57:1213-1217.
265. Calcinaro F, Gambelunghe G, Lafferty KJ. Protection from autoimmune diabetes by adjuvant therapy in the nonobese diabetic mouse: The role of interleukin-4 and interleukin-10. Immunology and Cell Biology 1997; 75:467-471
266. Rabinovitch A, Suarez-Pinzon WL, Sorensen O et al. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice: analysis of cytokine mRNA expression in the graft. Transplantation 1995; 60:368-374.
267. Moritani M, Yoshimoto K, Ii S et al. Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes. J Clin Invest 1996; 98:1851-1859.
268. Rulifson IC, Sperling AI, Fields PE et al. CD28 costimulation promotes the production of Th2 cytokines. J Immunol 1997; 158:658-665.
269. Lenschow DJ, Rhee L, Patel B et al. CD28/B7 regulation of Th1 and Th2 subsets in the development and progression of autoimmune diabetes. Immunity 1996; 5:285-293.
270. Takahashi K, Honeyman MC, Harrison LC. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J Immunol 1998; 161:2629-2635.
271. Ramsdell F, Seaman MS, Miller RE et al. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol 1994; 6:1545-1553.
272. Varadhachary AS, Perdow SM, Hu C et al. Differential ability of T cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci USA 1997; 94:5778-5783.
273. Zhang X, Brunner T, Carter L et al. Unequal death in T helper (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997; 185:1837-1849.
274. Serreze DV, Chapman HD, Post CM et al. Th1 to Th2 cytokine shifts in NOD mice: sometimes an outcome, rather than the cause of diabetes resistance elicited by immunostimulation. J Immunol 2001; 166:1352-1359.
275. Dalton DK, Haynes L, Chu C-Q et al. Interferon γ eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 2000; 192:117-122.
276. Parish NM, Hutchings PR, O'Reilly L et al. Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Immunol Rev 1995; 144:269-300.
277. Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 1998; 16:619-644.
278. Phillips JM, Harach SZ, Parish NM et al. Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic β cells. J Immunol 2000; 165:1949-1955.
279. Konieczny BT, Dai Z, Elwood ET et al. IFN-γ is critical for long-term allograft survival induced by blocking the CD28 and CD40L T cell costimulation pathways. J Immunol 1998; 160:2059-2064.
280. Diamond A, Gill RG. Biphasic roles for IFNγ in islet allograft immunity and tolerance. Transplantation 1999; 67:S23.
281. Dai Z, Konieczny BT, Baddoura FK et al. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998; 161:1659-1663.
282. Steiger B, Nickerson PW, Steurer W et al. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995; 155:489-498.
283. Falcone M, Yeung B, Tucker L et al. A defect in interleukin 12-induced activation and interferon γ secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus. J Exp Med 1999; 190:963-972.
284. Fujihira K, Nagata M, Moriyama H et al. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes 2000; 49:1998-2006.
285. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 1994; 43:613-621.
286. + cells in the pathogenesis of organ-specific autoimmune diseases. Immunology Today 1995; 16:34-38.
287. Charlton B, Lafferty KJ. The Th1/Th2 balance in autoimmunity. Curr Opin Immunol 1995; 7:793-798.
288. Delovitch T, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997; 7:727-738.
289. Wang B, Gonzalez A, Höglund P et al. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 1998; 47:1207-1211.
290. Pearce EJ, Cheever A, Leonard S et al. Schistosoma mansoni in IL-4-deficient mice. Int Immunol 1996; 8:435-444.
291. Noben-Trauth N, Kropf P, Muller I. Susceptibility to Leishmani major infection in interleukin-4-deficient mice. Science 1996; 271:987-990.
292. Kaufman DL, ClareSalzler M, Tian J et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366:69-72.
293. Tisch R, Yang X-D, Singer SM et al. Immune response to glutamic acid decarboxylase correlates with insulitis in nonobese diabetic mice. Nature 1993; 366:72-75.
294. Tisch R, Liblau RS, Yang X-D et al. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47:894-899.
295. Tisch R, Wang B, Serreze DV. Induction of GAD65-specific Th2 cells and suppression of autoimmune diabetes at lare stages of disease is epitope-dependent. J Immunol 1999 163; 1178-1187.
296. Tisch R, Wang B, Weaver DJ, et al. Antigen-specific mediated suppression of β cell autoimmunity by plasmid DNA vaccination. J Immunol 2001 166; 2122-2132.
297. Harrison LC, Honeyman MC, DeAizpurua HJ et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 1993; 341:1365-1369.
298. Yu L, Gianani R, Eisenbarth GS. Quantitation of glutamic acid decarboxylase autoantibody levels in prospectively evaluated relatives of patients with type I diabetes. Diabetes 1994; 43:1229-1233.
299. Ramiya V, Muir A, Maclaren N. Insulin prophylaxis in insulin-dependent diabetes mellitus. Immunological rationale and therapeutic use. Clin Immunother 1995; 3:177-183.
300. Alleva DG, Crowe PD, Jin L et al. (2001). A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 2001; 107:173-180.
301. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-chain (9-23). Proc Natl Acad Sci USA 1996; 93:956-960.
302. Polanski M, Melican NS, Zhang J et al. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a cotransfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 1997; 10:339-346.
303. Tian J, Atkinson MA, ClareSalzler MC et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183:1561-1567.
304. Ma S-W, Zhao D-L, Yin Z-Q et al. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Medicine 1997; 3:793-796.
305. Zhang ZJ, Davidson LE, Eisenbarth G et al. Suppression of diabetes in NOD mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991; 88:10252-10256.
306. + T cells that suppress adoptive transfer of diabetes. J Autoimmun 1994; 7:655-663.
307. Ploix C, Bergerot I, Fabien N et al. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes 1998; 47:39-44.
308. Harrison LC, Dempsey-Collier M, Kramer DR et al. Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996; 184:2167-2174.